Table 2

Subject demographic characteristics, allergic history, and threshold antigen concentration determined at inclusion

Placebo (n = 20)Levocabastine 0.05% (n = 20)Mequitazine (n = 20)Overall (n = 60)p Value
Age (years)
Mean (SD)23.3 (4.1)23.2 (3.8)27.4 (10.9)24.7 (7.2)Kruskal-Wallis
Min–max18–3318–3318–5118–510.83
Male sex7 (35%)7 (35%)10 (50%)24 (40%)χ2 0.53
Frequency of allergic symptoms, n (%)
2–4 times a year0 (0%)1 (5%)2 (10%)3 (5%)χ2
5–7 times a year1 (5%)0 (0%)0 (0%)1 (1.67%)0.74
All year long19 (95%)19 (95%)18 (90%)56 (93%)
Threshold allergen concentration, n (%)
1.25 (25%)13 (65%)9 (45%)27 (45%)
3.79 (45%)4 (20%)4 (20%)17 (28.3%)Kruskal-Wallis
114 (20%)1 (5%)5 (25%)10 (16.7%)0.10
332 (10%)2 (10%)2 (10%)6 (10%)